Thus, the main conclusions are: (i) B cell depletion in SLE is less efficient than RA; (ii) renal B cell infiltration following rituximab treatment is associated with poor outcomes; (iii) no significant relationships between the measured B cell intrinsic and extrinsic factors and the efficiency of BCD by rituximab; and (iv) obinutuzumab was superior to rituximab at inducing BCD in vitro, regardless of excess BAFF. The gene discussed is TNFSF13B; the disease is systemic lupus erythematosus.